PharmaTher Collaborates For Research On Psychedelic Microdosing Tech

PharmaTher Inc (CSE: PHRM) this morning announced that it will be conducting further research related to psychedelics. The company this morning entered into a sponsored research agreement with that of the Terasaki Institute to conduct a novel microneedle patch.

The microneedle patch to be researched and developed will look to deliver psychedelic pharmaceuticals through microdosing for unmet medical needs. Currently, the company is targeting the tech for use with psilocybin, MDMA, LSD, and DMT. The research will look to expand upon the microneedle tech currently held by the firm that was developed by the Khademhosseini Lab at UCLA.

The tech is reportedly focused on providing an alternative to oral administration, injections, topical and nasal delivery system, while overcoming certain drawbacks each method of administration currently has. Once developed, the company will look to obtain FDA approval for delivery of the psychedelic compounds for numerous needs, such as mental health, neurological and pain disorders.

“Our focus is pursuing prescription-based psychedelic pharmaceuticals for FDA and international regulatory approvals, and unlocking the potential therapeutic value of these compounds via a proprietary microneedle patch. We look forward to working with the Terasaki team lead by the Director and CEO of the Terasaki Institute, Dr. Ali Khademhosseini, in delivering next generation psychedelic pharmaceuticals with the aim to improve therapeutic and safety outcomes while potentially offering a differentiated product profile, improving patient compliance and enabling out-patient treatment options.”

Fabio Chianelli, CEO of PharmaTher

The current iteration of the microneedle technology, more formally referred to as GelMA, is reportedly safe and painless to use, while also demonstrating water-soluble and insoluble drugs with desirable release times.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

PharmaTher last traded at $0.37 on the CSE.


FULL DISCLOSURE: Pharmather is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pharmather on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

PharmaTher To Raise $10.0 Million Via Institutional Investor Financing

PharmaTher Holdings (CSE: PHRM) this morning indicated that the company has secured a financing with...

Friday, September 24, 2021, 08:28:12 AM

PharmaTher Receives FDA Approval For Ketamine Trial For Parkinson’s

PharmaTher Holdings (CSE: PHRM) has seen the US FDA approve the firms application for an...

Monday, May 17, 2021, 09:15:31 AM

Artificial Intelligence Meets Psychedelics – The Daily Dive feat Fabio Chianelli

Today on the Daily Dive, Fabio Chianelli, CEO of PharmaTher Inc (CSE: PHRM) sits down...

Tuesday, November 24, 2020, 01:00:00 PM

Revive Therapeutics Enters LOI To Acquire Psilocybin Program From PharmaTher

Revive Therapeutics (CSE: RVV) this morning announced that it has entered into a letter of...

Monday, December 21, 2020, 08:38:29 AM

PharmaTher Files Patent Application In US For Psilocybin Drug Combination To Treat Neurological Disorders

PharmaTher Inc (CSE: PHRM) this morning announced that it has filed a provisional patent application...

Tuesday, December 15, 2020, 09:00:13 AM